The Top 5 Biosimilar Articles for the Week of November 27

News
Video

Here are the top 5 biosimilar articles for the week of November 27, 2023.

Number 5: Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

Number 4: Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).

Number 3: Biosimilar experts highlight the persisting confusion around interchangeability designations for biosimilars, including misunderstandings about the definition of interchangeability and the purpose these labels serve.

Number 2: As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Number 1: Sarfaraz K. Niazi, PhD, offers hope for the end of interchangeability labels in the United States in his latest column.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
The Top 5 Biosimilar Articles for the Week of February 19, 2024.
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
The top 5 biosimilar articles for the week of February 5, 2024.
The Top 5 Biosimilar Articles for the Week of January 29
Here are the top 5 biosimilar articles for the week of January 15, 2024.
The Top 5 Center for Biosimilars Articles for the Week of January 8, 2024.
Prerakkumar Parikh, PharmD
Here are the top 5 biosimilar articles for the week of January 1, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.